Next 10 |
home / stock / clrb / clrb articles
FLORHAM PARK, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company ...
FLORHAM PARK, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company ...
FLORHAM PARK, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical compan...
Monday, Cellectar Biosciences Inc (NASDAQ:CLRB) announced that iopofosine I 131 combined with external beam radiation therapy (EBRT) was ...
FLORHAM PARK, N.J., Jan. 12, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company...
Cellectar Biosciences Inc (NASDAQ: CLRB) announced data from its CLOVER WaM pivotal study, evaluating iopofosine I 131, a targeted radiotherap...
Management to host conference call on Monday, January 8, 2024, at 8:00 am ET Company also to present at the Biotech Showcase FLORHAM PARK, N.J., J...
FLORHAM PARK, N.J., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company...
Reports Preliminary Financial Results for Third Quarter 2023 and Provides a Corporate Update Conference Call scheduled for today at 8:30 am Easter...
News, Short Squeeze, Breakout and More Instantly...
Cellectar Biosciences Inc. Company Name:
CLRB Stock Symbol:
NASDAQ Market:
Cellectar Biosciences Inc. Website:
Management to host a conference call today at 8:30 am ET WM pivotal study data to be announced in June FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, develop...
FLORHAM PARK, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company ...
FLORHAM PARK, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that Jarrod Longcor, chief operating ...